Wheeler Bio announced the appointment of Rajesh Beri, Ph.D., as Chief Development Officer. The appointment of Dr. Beri is the latest in a series of steps Wheeler Bio has taken to deepen its scientific expertise and expand its capabilities to better serve clinical- and commercial-focused, antibody-based development clients.
With more than 30 years of experience in the biotechnology industry, Rajesh has led over 70 biologics programs across multiple therapeutic modalities, from preclinical research through commercial manufacturing. His expertise in CMC strategy, technical operations, process development, and cGMP manufacturing strengthens Wheeler Bio's ModularCMC® platform and supports the accelerated development of biologics.
"We are excited to welcome Rajesh to Wheeler Bio as Chief Development Officer," said Patrick Lucy, President and CEO of Wheeler Bio. "Rajesh has built an exceptional career leading biologics development and advancing antibody-based molecules from early development through commercialization. His leadership will increase the scientific rigor at Wheeler Bio and ensure the excellent execution of process, formulation, and analytical development that our clients require."
Dr. Beri earned his Ph.D. in Chemical Engineering from Worcester Polytechnic Institute and spent fourteen years in senior leadership roles at Lonza Biologics before holding executive leadership positions at Immunovant, Goodwin Biotech, and Senda Biosciences.
As Chief Development Officer, Dr. Beri will lead Wheeler Bio's development organization, supporting integrated CMC programs from cell line development through Drug Substance and Drug Product manufacturing. He will oversee the scientific strategy supporting Wheeler Bio's signature ModularCMC® platform, with an eye on continuous improvement while delivering to our partners a CMC strategy that reduces risk, improves scalability, and accelerates timelines.
"I am honored to join Wheeler Bio during this exciting period of growth," said Dr. Beri. "The company's scientific depth, collaborative culture, and innovative ModularCMC® platform create an opportunity to help biotechnology companies overcome development challenges with flexible, phase-appropriate CMC solutions. I look forward to working alongside the talented Wheeler Bio team and providing technical support to Wheeler's partners to help advance their programs and ultimately deliver new therapies to patients."